457 related articles for article (PubMed ID: 12542733)
1. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP.
Colovic M; Dimitrijevic M; Sonnenburg C; Suvajdzic N; Donfrid M; Bogdanovic A
Hematol J; 2003; 4(5):358-62. PubMed ID: 14502262
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
[TBL] [Abstract][Full Text] [Related]
5. Gammaplex
Wasserman RL
Immunotherapy; 2017 Oct; 9(13):1071-1088. PubMed ID: 29032734
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP).
Hong J; Bang SM; Mun YC; Yhim HY; Lee J; Lim HS; Oh D;
J Korean Med Sci; 2018 May; 33(19):e142. PubMed ID: 29736158
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of intravenous immunoglobulin (Flebogamma
Apte S; Navarro-Puerto J; Damodar S; Ramanan V; John J; Kato G; Ross C; Shah C; Torres M; Fu C'; Rucker K; Pinciaro P; Barrera G; Aragonés ME; Ayguasanosa J
Immunotherapy; 2019 Feb; 11(2):81-89. PubMed ID: 30499734
[TBL] [Abstract][Full Text] [Related]
9. A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.
Kreuz W; Erdös M; Rossi P; Bernatowska E; Espanol T; Maródi L
Clin Exp Immunol; 2010 Sep; 161(3):512-7. PubMed ID: 20550545
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura.
Julia A; Kovaleva L; Loria S; Alberca I; Hernandez F; Sandoval V; Sierra J; Vidaller A; Ayguasanosa J; Carretero M
Transfus Med; 2009 Oct; 19(5):260-8. PubMed ID: 19747289
[TBL] [Abstract][Full Text] [Related]
11. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases.
Schiff RI; Williams LW; Nelson RP; Buckley RH; Burks W; Good RA
J Clin Immunol; 1997 Jan; 17(1):21-8. PubMed ID: 9049782
[TBL] [Abstract][Full Text] [Related]
12. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a new intravenous immunoglobulin (Panzyga
Arbach O; Taumberger AB; Wietek S; Cervinek L; Salama A
Transfus Med; 2019 Feb; 29(1):48-54. PubMed ID: 30687970
[TBL] [Abstract][Full Text] [Related]
14. Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia.
Spadaro G; Vultaggio A; Alberto Bosi A; Reichert D; Janssen J; Lamacchia D; Nappi L; Pecoraro A; Milito C; Ferraro A; Matucci A; Bacchiarri F; Carrai V; Hibbeler A; Speckman E; Guarnieri C; Bongiovanni S; Quinti I
Int Immunopharmacol; 2017 Mar; 44():38-42. PubMed ID: 28073042
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075).
Dash CH; Gillanders KR; Stratford Bobbitt ME; Gascoigne EW; Leach SJ
PLoS One; 2014; 9(6):e96600. PubMed ID: 24892422
[TBL] [Abstract][Full Text] [Related]
16. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
17. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID).
Viallard JF; Brion JP; Malphettes M; Durieu I; Gardembas M; Schleinitz N; Hoarau C; Lazaro E; Puget S
Rev Med Interne; 2017 Sep; 38(9):578-584. PubMed ID: 28683953
[TBL] [Abstract][Full Text] [Related]
18. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life.
Bussel JB; Eldor A; Kelton JG; Varon D; Brenner B; Gillis S; Angiolillo A; Kulkarni R; Abshire TC; Kelleher J;
Thromb Haemost; 2004 Apr; 91(4):771-8. PubMed ID: 15045139
[TBL] [Abstract][Full Text] [Related]
19. Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations.
Andresen I; Kovarik JM; Spycher M; Bolli R
J Clin Pharmacol; 2000 Jul; 40(7):722-30. PubMed ID: 10883413
[TBL] [Abstract][Full Text] [Related]
20. Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial.
Benesch M; Kerbl R; Lackner H; Berghold A; Schwinger W; Triebl-Roth K; Urban C
J Pediatr Hematol Oncol; 2003 Oct; 25(10):797-800. PubMed ID: 14528103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
